Christopher W. Chiu

Head of Multiple Myeloma and Leukemia TR

J&J Innovative Medicine

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Christopher W. Chiu is the Head of Multiple Myeloma and Leukemia Translational Research at J&J Innovative Medicine in the United States. His research focuses on novel therapeutic strategies for hematological malignancies, particularly through bispecific antibodies such as epcoritamab and the role of immunotherapeutic combinations in optimizing treatment for multiple myeloma and B-cell lymphomas. He has published extensively on the pharmacokinetic and pharmacodynamic modeling of targeted therapies and their implications for clinical practice.

Articles (10)

Year:

2025

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (3)

Roberto Oliveri

Head of Medical Translational Development

NORWAY

View details

Oliver Treacy

Lecturer Above the Bar

Ollscoil na Gaillimhe – University of Galway

IRELAND

View details

Thomas Ritter

University of Galway

IRELAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Christopher W. Chiu

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B‐Cell Lymphoma

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting

Semimechanistic Physiologically-Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B-Cell Lymphomas.

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.

Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis.

Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR

Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study

Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens

Collaborators (3)

Roberto Oliveri

Oliver Treacy

Thomas Ritter

Make your next move.